Multicenter comparison of transcatheter aortic valve implantation with the self-expanding ACURATE neo2 versus Evolut PRO transcatheter heart valves.
ACURATE Neo2
Evolut PRO
Self-expanding
Transcatheter aortic valve implantation
Transcatheter heart valves
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
28 Apr 2023
28 Apr 2023
Historique:
received:
20
10
2022
accepted:
27
03
2023
pubmed:
28
4
2023
medline:
28
4
2023
entrez:
28
4
2023
Statut:
aheadofprint
Résumé
New-generation self-expanding transcatheter aortic heart valves (THV) were designed to overcome technical constraints of their preceding generations. We sought to compare the efficacy and safety of the self-expanding ACURATE neo2 (Neo2) versus Evolut PRO (PRO) devices. Seven hundred nine patients undergoing transfemoral transcatheter aortic valve implantation (TAVI) with either Neo2 (n = 496) or PRO (n = 213) were included. Propensity score matching (PSM) was performed to account for differences in baseline characteristics. In-hospital and 30-day clinical outcomes were evaluated according to Valve Academic Research Consortium-3 criteria. Baseline characteristics were comparable between both groups after PSM (Neo2: n = 155, Evolut Pro: n = 155). Technical success rates were high in both groups (Neo2: 94.8% vs PRO: 97.4%; p = 0.239). Need for permanent pacemaker implantation was less frequent with Neo2 compared with PRO (7.5% vs 20.6%; p = 0.002), whereas major vascular complications were more frequent with Neo2 (Neo2: 11.6% vs PRO: 4.5%; p = 0.022). Intended valve performance at discharge was high in both groups without relevant differences among groups (Neo2: 97.4% vs. 95.3%; p = 0.328). Short-term outcomes after TAVI using latest-generation self-expanding THV were excellent, with overall low rates of adverse events. However, Neo2 was associated with lower pacemaker rates and reduced the prevalence of moderate-severe paravalvular leakage. Transprosthetic gradients after TAVI were higher with Neo2 compared with PRO.
Sections du résumé
BACKGROUND
BACKGROUND
New-generation self-expanding transcatheter aortic heart valves (THV) were designed to overcome technical constraints of their preceding generations. We sought to compare the efficacy and safety of the self-expanding ACURATE neo2 (Neo2) versus Evolut PRO (PRO) devices.
METHODS
METHODS
Seven hundred nine patients undergoing transfemoral transcatheter aortic valve implantation (TAVI) with either Neo2 (n = 496) or PRO (n = 213) were included. Propensity score matching (PSM) was performed to account for differences in baseline characteristics. In-hospital and 30-day clinical outcomes were evaluated according to Valve Academic Research Consortium-3 criteria.
RESULTS
RESULTS
Baseline characteristics were comparable between both groups after PSM (Neo2: n = 155, Evolut Pro: n = 155). Technical success rates were high in both groups (Neo2: 94.8% vs PRO: 97.4%; p = 0.239). Need for permanent pacemaker implantation was less frequent with Neo2 compared with PRO (7.5% vs 20.6%; p = 0.002), whereas major vascular complications were more frequent with Neo2 (Neo2: 11.6% vs PRO: 4.5%; p = 0.022). Intended valve performance at discharge was high in both groups without relevant differences among groups (Neo2: 97.4% vs. 95.3%; p = 0.328).
CONCLUSIONS
CONCLUSIONS
Short-term outcomes after TAVI using latest-generation self-expanding THV were excellent, with overall low rates of adverse events. However, Neo2 was associated with lower pacemaker rates and reduced the prevalence of moderate-severe paravalvular leakage. Transprosthetic gradients after TAVI were higher with Neo2 compared with PRO.
Identifiants
pubmed: 37115228
doi: 10.1007/s00392-023-02194-4
pii: 10.1007/s00392-023-02194-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Members WC, Otto CM, Nishimura RA et al (2021) 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 77:450–500
doi: 10.1016/j.jacc.2020.11.035
Rheude T, Pellegrini C, Allali A et al (2022) Multicenter comparison of latest-generation balloon-expandable versus self-expanding transcatheter heart valves: Ultra versus Evolut. Int J Cardiol 357:115–120
Scotti A, Pagnesi M, Kim W-K et al (2022) Haemodynamic performance and clinical outcomes of transcatheter aortic valve replacement with the self-expanding ACURATE neo2. EuroIntervention 18:804–811
doi: 10.4244/EIJ-D-22-00289
pubmed: 35678222
Rheude T, Pellegrini C, Lutz J et al (2020) Transcatheter aortic valve replacement with balloon-expandable valves: comparison of SAPIEN 3 ultra versus SAPIEN 3. JACC Cardiovasc Interv 13:2631–2638
doi: 10.1016/j.jcin.2020.07.013
pubmed: 33129822
Mack MJ, Leon MB, Thourani VH et al (2019) Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380:1695–1705
doi: 10.1056/NEJMoa1814052
pubmed: 30883058
Popma JJ, Deeb GM, Yakubov SJ et al (2019) Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med 380:1706–1715
doi: 10.1056/NEJMoa1816885
pubmed: 30883053
Tamburino C, Bleiziffer S, Thiele H et al (2020) Comparison of self-expanding bioprostheses for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: SCOPE 2 randomized clinical trial. Circulation 142:2431–2442
doi: 10.1161/CIRCULATIONAHA.120.051547
pubmed: 33054367
Lanz J, Kim W-K, Walther T et al (2019) Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial. Lancet 394:1619–1628
doi: 10.1016/S0140-6736(19)32220-2
pubmed: 31570258
Buono A, Gorla R, Ielasi A et al (2022) Transcatheter aortic valve replacement with self-expanding ACURATE neo2: postprocedural hemodynamic and short-term clinical outcomes. JACC Cardiovasc Interv 15:1101–1110
doi: 10.1016/j.jcin.2022.02.027
pubmed: 35595675
Möllmann H, Holzhey DM, Hilker M et al (2021) The ACURATE neo2 valve system for transcatheter aortic valve implantation: 30-day and 1-year outcomes. Clin Res Cardiol 110:1912–1920
doi: 10.1007/s00392-021-01882-3
pubmed: 34148125
pmcid: 8639565
Pellegrini C, Rheude T, Renker M et al (2022) ACURATE neo2 versus SAPIEN 3 Ultra for transcatheter aortic valve implantation. EuroIntervention 18:987–995
doi: 10.4244/EIJ-D-22-00164
Manoharan G, Grube E, Van Mieghem NM et al (2020) Thirty-day clinical outcomes of the Evolut PRO self-expanding transcatheter aortic valve: the international FORWARD PRO study. EuroIntervention 16:850–857
doi: 10.4244/EIJ-D-20-00279
pubmed: 32748789
Committee V-3 W, VARC-3 WRITING COMMITTEE, Généreux P et al (2021) Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J 42:1825–1857
doi: 10.1093/eurheartj/ehaa799
Voigtländer L, Kim W-K, Mauri V et al (2021) Transcatheter aortic valve implantation in patients with a small aortic annulus: performance of supra-, intra- and infra-annular transcatheter heart valves. Clin Res Cardiol 110:1957–1966
doi: 10.1007/s00392-021-01918-8
pubmed: 34387736
pmcid: 8639544
Husser O, Kim W-K, Pellegrini C et al (2017) Multicenter comparison of novel self-expanding versus balloon-expandable transcatheter heart valves. JACC Cardiovasc Interv 10:2078–2087
doi: 10.1016/j.jcin.2017.06.026
pubmed: 29050625
Abdel-Wahab M, Mehilli J, Frerker C et al (2014) Comparison of balloon-expandable vs self-expandable valves in patients undergoing transcatheter aortic valve replacement: the CHOICE randomized clinical trial. JAMA 311:1503–1514
doi: 10.1001/jama.2014.3316
pubmed: 24682026
Forrest JK, Kaple RK, Tang GHL et al (2020) Three generations of self-expanding transcatheter aortic valves: a report from the STS/ACC TVT Registry. JACC Cardiovasc Interv 13:170–179
doi: 10.1016/j.jcin.2019.08.035
pubmed: 31973793
Pagnesi M, Kim W-K, Conradi L et al (2019) Transcatheter aortic valve replacement with next-generation self-expanding devices: a multicenter, retrospective, propensity-matched comparison of Evolut PRO versus acurate neo transcatheter heart valves. JACC Cardiovasc Interv 12:433–443
doi: 10.1016/j.jcin.2018.11.036
pubmed: 30846081
Bruno F, D’Ascenzo F, Vaira MP et al (2021) Predictors of pacemaker implantation after transcatheter aortic valve implantation according to kind of prosthesis and risk profile: a systematic review and contemporary meta-analysis. Eur Heart J Qual Care Clin Outcomes 7:143–153
doi: 10.1093/ehjqcco/qcaa089
pubmed: 33289527
van Rosendael PJ, Delgado V, Bax JJ (2018) Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: a systematic review. Eur Heart J 39:2003–2013
doi: 10.1093/eurheartj/ehx785
pubmed: 29420704
Forrest JK, Mangi AA, Popma JJ et al (2018) Early outcomes with the Evolut PRO repositionable self-expanding transcatheter aortic valve with pericardial wrap. JACC Cardiovasc Interv 11:160–168
doi: 10.1016/j.jcin.2017.10.014
pubmed: 29348010
Grube E, Van Mieghem NM, Bleiziffer S et al (2017) Clinical outcomes with a repositionable self-expanding transcatheter aortic valve prosthesis: the International FORWARD Study. J Am Coll Cardiol 70:845–853
doi: 10.1016/j.jacc.2017.06.045
pubmed: 28797353
Tang GHL, Zaid S, Michev I et al (2018) “Cusp-Overlap” view simplifies fluoroscopy-guided implantation of self-expanding valve in transcatheter aortic valve replacement. JACC Cardiovasc Interv 11:1663–1665
doi: 10.1016/j.jcin.2018.03.018
pubmed: 30139479
Pascual I, Hernández-Vaquero D, Alperi A et al (2022) Permanent pacemaker reduction using cusp-overlapping projection in TAVR: a propensity score analysis. JACC Cardiovasc Interv 15:150–161
doi: 10.1016/j.jcin.2021.10.002
pubmed: 35057985
Aladham A, Gada H, Wang Y et al (2022) Incidence of permanent pacemaker implantation using the cusp overlap technique: a large single-center analysis. JACC Cardiovasc Interv 15:1006–1008
doi: 10.1016/j.jcin.2022.03.005
pubmed: 35512914
Costa G, Zappulla P, Barbanti M et al (2019) Pacemaker dependency after transcatheter aortic valve implantation: incidence, predictors and long-term outcomes. EuroIntervention 15:875–883
doi: 10.4244/EIJ-D-18-01060
pubmed: 31217147
Faroux L, Chen S, Muntané-Carol G et al (2020) Clinical impact of conduction disturbances in transcatheter aortic valve replacement recipients: a systematic review and meta-analysis. Eur Heart J 41:2771–2781
doi: 10.1093/eurheartj/ehz924
pubmed: 31899484
Rück A, Kim W-K, Kawashima H et al (2021) Paravalvular aortic regurgitation severity assessed by quantitative aortography: ACURATE neo2 versus ACURATE neo transcatheter aortic valve implantation. J Clin Med 10:4627
doi: 10.3390/jcm10204627
pubmed: 34682750
pmcid: 8539505
Chau K, Chau KC, Chen S et al (2022) Paravalvular regurgitation after transcatheter aortic valve replacement in intermediate-risk patients: a pooled PARTNER 2 study. EuroIntervention 17:1053–1060
doi: 10.4244/EIJ-D-20-01293
pubmed: 34483095
pmcid: 9724907
Ludman PF, Moat N, de Belder MA et al (2015) Transcatheter aortic valve implantation in the United Kingdom: temporal trends, predictors of outcome, and 6-year follow-up: a report from the UK Transcatheter Aortic Valve Implantation (TAVI) Registry, 2007 to 2012. Circulation 131:1181–1190
doi: 10.1161/CIRCULATIONAHA.114.013947
pubmed: 25637628
Zahn R, Werner N, Gerckens U et al (2017) Five-year follow-up after transcatheter aortic valve implantation for symptomatic aortic stenosis. Heart 103:1970–1976
pubmed: 28684438
Okuno T, Tomii D, Heg D et al (2022) Five-year outcomes of mild paravalvular regurgitation after transcatheter aortic valve implantation. EuroIntervention 18:33–42
doi: 10.4244/EIJ-D-21-00784
pubmed: 34930717
pmcid: 9904370
Regazzoli D, Chiarito M, Cannata F et al (2020) Transcatheter self-expandable valve implantation for aortic stenosis in small aortic annuli: the TAVI-SMALL Registry. JACC Cardiovasc Interv 13:196–206
doi: 10.1016/j.jcin.2019.08.041
pubmed: 31883714
Abdelghani M, Mankerious N, Allali A et al (2018) Bioprosthetic valve performance after transcatheter aortic valve replacement with self-expanding versus balloon-expandable valves in large versus small aortic valve annuli: insights from the CHOICE Trial and the CHOICE-Extend Registry. JACC Cardiovasc Interv 11:2507–2518
doi: 10.1016/j.jcin.2018.07.050
pubmed: 30503595
Rheude T, Pellegrini C, Cassese S et al (2020) Predictors of haemodynamic structural valve deterioration following transcatheter aortic valve implantation with latest-generation balloon-expandable valves. EuroIntervention 15:1233–1239
doi: 10.4244/EIJ-D-19-00710
pubmed: 31498111
Rheude T, Pellegrini C, Stortecky S et al (2021) Meta-analysis of bioprosthetic valve thrombosis after transcatheter aortic valve implantation. Am J Cardiol 138:92–99
doi: 10.1016/j.amjcard.2020.10.018
pubmed: 33065085